Sezzle (SEZL) shares fell roughly 31.6% over the trailing 30 days, declining from about $174.24 to $119.11. The decline was triggered by Sezzle's second-quarter 2026 report, which beat estimates and raised full-year guidance but flagged slowing second-half growth.

TTM Technologies shares closed at $110.54 on August 21, 2026, down roughly 24% over the prior 30 days from $144.70 on July 22, 2026. The decline occurred despite record second-quarter results, including revenue of $1.0 billion (up 37% year over year) and non-GAAP earnings of $0.99 per share, with raised full-year guidance.

Sterling Infrastructure (STRL) declined roughly -28% over the last 30 days, falling from about $719 on July 22 to a closing price of $516.81 on August 21, 2026. The pullback followed an extraordinary rally that pushed shares to a 52-week intraday high of $1,005.68 in early June before sentiment reversed.

Hut 8 shares fell roughly 26% over the last 30 days, from about $109.86 at the July 22 close to $80.86 at the August 21 close. The decline was driven by a second-quarter earnings miss, a large digital-asset mark-to-market loss tied to Bitcoin's weakness, and profit-taking across AI-pivoting Bitcoin miners.

Core Scientific shares fell roughly 22% over the trailing 30 days, sliding from about $22.75 in late July to a close near $17.81, well below their 52-week high of $30.46. The pullback occurred despite strong top-line growth, as second-quarter 2026 revenue more than doubled year over year to $164.2 million.

The selected price target is $11 per share , the highest current analyst target and a level just above the stock's 52-week high of $10.05. Butterfly Network has delivered record quarterly revenue, raised its full-year guidance, and holds a "Strong Buy" consensus, the strongest bullish factors supporting further upside.

Selected price target: $15 per share, roughly 25% above recent trading levels near $12 and about 17% above the 52-week high of $12.85. Bullish factors: A recovery in the animal-safety business, improving food-safety margins, portfolio simplification through divestitures, and a series of analyst target increases.

SSMR shares climbed about 24.6% over the past 30 days, rising from a closing price of $14.96 on July 22, 2026, to $18.64 by August 21, 2026. The rally has been fueled by rising silver prices, a strengthening industrial and AI-related demand narrative, and encouraging underground drill results at the Sunshine Mine.

Aveanna Healthcare (AVAH) climbed roughly 39% over the trailing 30 days, rising from about $9.45 to above $13. The move was driven primarily by a stronger-than-expected second-quarter report and a raised full-year outlook announced August 13, 2026.

AMPL shares climbed roughly 52% over the past 30 days, rising from a close of $8.74 on July 22 to $13.29 on August 21. The advance extends a broader rally, with the stock more than doubling over the trailing quarter from around $6.50.

Uranium Royalty (UROY) gained roughly 48% over the trailing 30 days, climbing from about $2.96 to around $4.38 per share, and is up approximately 27% over the last quarter. The move was driven by the July 27, 2026 completion of the $1.14 billion Sweetwater arrangement, which transformed the company into a diversified uranium and land royalty business.

Target in focus: Investors are asking whether TOP Financial Group (TOP) can climb to a $20 share price, roughly 40% above recent levels. Strongest bullish factors: Powerful 52-week momentum, a recently restructured share count, and a low float that can amplify upward moves.

IE shares climbed roughly 23% over the 30 days through mid-August 2026, rebounding from a 52-week low near $7.86 in mid-July to close at $11.27 on August 21, 2026. The recovery was supported by renewed momentum at the Santa Cruz Copper Project, including a tunnel boring machine acquisition and an updated Preliminary Feasibility Study targeted for September 2026.

The central question is whether Americas Gold and Silver Corporation (USAS) can climb from its recent level near $5.39 to the widely discussed $10 mark, a gain of roughly 85%. Wall Street is broadly constructive: the consensus rating is "Buy" or "Strong Buy," with average 12-month price targets clustering between roughly $9.25 and $9.75 — just below $10.

The selected price target is $20 per share , a psychological round-number level roughly 8% above recent trading near $18.40 and just above the stock's 52-week high. The strongest bullish factor is the pending acquisition by Tempus AI (TEM) at $16.25 per share, with shares trading above that price as investors weigh potential competing bids or a sweetened offer.

PURR shares climbed roughly 54.5% over the 30-day period ending August 21, 2026, rising from a July 22 close of $6.85 to $10.58. The sharpest leg came on August 19, when the stock jumped about 30% in a single session after President Donald Trump said the CFTC was working to bring Hyperliquid into the U.S. in a compliant manner.

The central question is whether Trulieve Cannabis Corp. (TRLV) can climb to a $15 price target , the lowest point of the current analyst range and a round-number milestone above its 52-week high. The strongest bullish factors include Trulieve's status as the first U.S. cannabis company listed on the New York Stock Exchange, strong cash generation, and federal rescheduling of medical marijuana to Schedule III.

The target: $10 per share, a psychological round-number milestone roughly 16% above MRVI's latest close near $8.64. Bullish case: A sharp earnings-driven rally, accelerating GMP (Good Manufacturing Practice) consumables demand, expanding margins, and a materially strengthened balance sheet.

FIGS shares climbed roughly 48% over the last 30 days, rising from about $9.92 in late July to $14.68 at the most recent close. The surge was driven by a second-quarter earnings beat that came in well above Wall Street expectations, plus a raised full-year outlook.

The target: Investors are increasingly asking whether PGEN can reach $15, a level that would roughly double its recent price and sit between the consensus analyst target of $14.50 and the Street-high target of $18. Strongest bullish factor: Full FDA approval of its lead therapy PAPZIMEOS, plus seven years of orphan-drug exclusivity through 2032, gives the company a rare, protected revenue runway.